Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Paul A Vanderlaan, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Paul Vanderlaan and Yael Heher.
Connection Strength

2.914
  1. Pre-analytic error: A significant patient safety risk. Cancer Cytopathol. 2018 08; 126 Suppl 8:738-744.
    View in: PubMed
    Score: 0.793
  2. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target. Clin Lung Cancer. 2018 09; 19(5):e589-e590.
    View in: PubMed
    Score: 0.780
  3. Measuring and assuring quality performance in cytology: A toolkit. Cancer Cytopathol. 2017 06; 125(S6):502-507.
    View in: PubMed
    Score: 0.731
  4. Using the Model for Improvement and Plan-Do-Study-Act to effect SMART change and advance quality. Cancer Cytopathol. 2021 01; 129(1):9-14.
    View in: PubMed
    Score: 0.228
  5. False positive diagnosis of lymph node metastases in a 34-year-old woman with a history of extraskeletal myxoid chondroscarcoma: A root cause analysis. Cancer Cytopathol. 2019 02; 127(2):69-71.
    View in: PubMed
    Score: 0.202
  6. Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis. Clin Lung Cancer. 2017 09; 18(5):e349-e356.
    View in: PubMed
    Score: 0.180
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.